<DOC>
	<DOCNO>NCT01258738</DOCNO>
	<brief_summary>This two part study . During period one comparison Etanercept ( ETN ) placebo arm maintain background anti inflammatory drug prescribe Physician . The hypothesis Etanercept superior placebo arm determine proportion subject achieve Assessments Ankylosing Spondylitis ( ASAS ) 40 improvement 12 week . This follow 92 week extension everyone trial receives Etanercept ( ETN ) background non steroidal anti inflammatory drug ( NSAID ) .</brief_summary>
	<brief_title>Study Comparing Etanercept ( ETN ) Against Placebo Etanercept Background Nonsteroidal Anti Inflammatory Drug ( NSAIDs ) Treatment Early Spondyloarthritis ( SpA ) Patients Who Not Have X-ray Structural Changes</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Diagnosis axial spondyloarthritis define Assessments Ankylosing Spondylitis ( ASAS ) criterion Active symptom define Ankylosing Spondylitis Disease Activity Index { BASDAI ) &gt; = 4 Axial symptom back pain less favorable response steroidal anti inflammatory drug optimal dosage great 4 week Evidence current recent episode uveitis Evidence IBD flare within 6 month Previous treatment anti Tumor necrosis factor ( TNF ) Active tuberculosis Radiographic sacroiliitis grade 34 unilaterally &gt; = 2 bilaterally</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Early ankylose spondylitis ( SpA ) study ; efficacy safety health come</keyword>
</DOC>